Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6797993 | Journal of the American Academy of Child & Adolescent Psychiatry | 2013 | 11 Pages |
Abstract
The achievement of remission had a beneficial effect on anxiety, ADHD, and DBD symptoms, regardless of the type of treatment received. There were no differential effects of medication or CBT on outcome, except for a nonsignificant trend that those adolescents treated with SSRIs showed a greater decrease in rates of comorbid DBDs relative to those treated with venlafaxine. Clinical trial registration information-Treatment of SSRI-Resistant Depression In Adolescents (TORDIA); http://clinicaltrials.gov/; NCT00018902.
Related Topics
Health Sciences
Medicine and Dentistry
Perinatology, Pediatrics and Child Health
Authors
Robert C. M.Ed., M.S.-III, Manivel B.A., M.S.-III, Brandon M.S., M.S.-III, Jiayan M.S., Taryn M.S., Graham J. M.D., Giovanna M.S., Greg N. Ph.D., Karen Dineen M.D., Ph.D., Boris M.D., Martin B. M.D., Neal M.D., Wael M.D., Joan Rosenbaum Ph.D.,